If your autistic child cannot switch off, is still awake at midnight, and you are googling this at 2am while waiting for CAMHS or paediatrics — this is the rare guide where the evidence is actually pretty good.
Yes — for many autistic children, melatonin genuinely helps them fall asleep faster and (in prolonged-release form) sleep longer. It is not magic. It works best alongside a steady bedtime routine, and only after obvious medical causes have been ruled out. In the UK, Slenyto is the licensed prolonged-release option for autism-related insomnia, prescribed by paediatrics, sleep clinics or CAMHS — not bought over the counter.
That summary holds up because, compared with most autism interventions, the evidence here is unusually solid. Trials such as MENDS and the later prolonged-release melatonin studies showed melatonin can help children fall asleep faster, and the right formulation can also improve total sleep time. In the UK, Slenyto is the first MHRA-licensed paediatric prolonged-release melatonin for insomnia in children and adolescents aged 2 to 18 with autism spectrum disorder and/or Smith-Magenis syndrome, when behavioural sleep measures have not been enough.
Autistic children are much more likely to have insomnia, delayed sleep onset, night waking, early waking, and very fragile sleep routines. There are several reasons for that:
The real question is not just "Should we try melatonin?" It is whether melatonin is the right tool for the specific sleep problem this child has.
The MENDS trial matters because it was practical and NHS-relevant. Children with neurodevelopmental disorders and severe sleep problems first had a behavioural intervention period. Only the children who did not improve were randomised — which reflects real life: routine first, medication after.
MENDS found that melatonin improved total sleep time by about 22 minutes on sleep diaries and shortened time to fall asleep significantly. The catch was that some children also woke earlier, so the main gain was often in getting to sleep rather than magically creating perfect nights.
A good response may look like bedtime becoming manageable, not your child suddenly sleeping perfectly.
A 2017 Cochrane review looking at melatonin for non-respiratory sleep disorders in children with neurodevelopmental disorders supported the basic picture: melatonin is useful for some children, particularly around sleep onset, but should be used thoughtfully and alongside proper assessment rather than as a lazy default.
More recent autism-specific reviews have been more upbeat. A 2023 systematic review and meta-analysis found melatonin improved total sleep time, how quickly people fell asleep, and overall sleep quality. Night waking improved less consistently. That fits the real-world clinical picture quite well.
So yes, this evidence base is positive — not perfect, but clearly better than the evidence for things like oxytocin or many expensive private interventions marketed to autistic families.
The big step forward came with a child-friendly prolonged-release melatonin tablet — the formulation that became Slenyto. In the Phase 3 placebo-controlled trial, children and adolescents whose sleep had not improved with behavioural intervention alone slept on average 57.5 minutes longer with this treatment compared with 9.1 minutes with placebo after 13 weeks. They also fell asleep much faster: on average 39.6 minutes earlier versus 12.5 minutes with placebo.
That is exactly the sort of result that explains why this product ended up licensed.
Slenyto is not just "melatonin in a nicer box". It is a prolonged-release formulation designed for children who not only struggle to drop off but may also struggle to stay asleep.
In the UK, it is the first MHRA-licensed paediatric prolonged-release melatonin for insomnia in children and adolescents aged 2 to 18 with autism spectrum disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.
That licensing point matters. It means a product, dose form and evidence package were formally reviewed for this use. In most NHS areas, Slenyto is specialist-initiated through community paediatrics, a sleep clinic, or CAMHS rather than a GP starting it cold in a ten-minute appointment.
Licensed. Prolonged-release. Autism-specific indication. Best when the problem includes both sleep onset and poor sleep maintenance, and when the child fits the licensed pathway.
This has been used in UK paediatric practice for years. It can be very helpful for children who mainly struggle to fall asleep, but is often less helpful for repeated night waking.
These are where things get muddy. Parents see melatonin gummies and tablets online or on holiday in the US and understandably think: why am I waiting months for something Americans can buy next to shampoo?
The problem is that imported OTC products vary wildly in dose, quality control, and actual content. Some studies of US supplements have found that labelled melatonin content and real melatonin content do not always match. That is not ideal when you are dosing a tired autistic child.
In plain English: you cannot just buy real melatonin as a normal food supplement on the UK high street. In UK shops, "sleep support" products are usually something else — magnesium, herbs, or a blend — not straightforward medicinal melatonin.
Usually it looks like this:
Typical wait? Frustratingly, often months. If your child is not yet under paediatrics or CAMHS, that wait can be longer.
Right to Choose can sometimes help with assessment pathways, but it is not a fast-track to your GP freely prescribing Slenyto tomorrow. Melatonin prescribing still usually sits inside local paediatric, CAMHS or formulary rules.
Bring a 2-week sleep diary if you can. Then ask:
If you are in Kent, ask what the local sleep pathway is, whether community paediatrics can initiate melatonin, and whether a sleep diary is required before review.
This part bores people, which is exactly why it gets skipped.
No melatonin replaces routine. If bedtime is drifting, screens are bright, the room is sensory hell, and the child is anxious or hungry or constipated, melatonin may help a bit — but it will not rescue a chaotic setup.
Good sleep work still means:
If sensory overload is a big part of bedtime battles, start with our guide to sensory processing difficulties in children. If you are still in the early diagnosis fog, our first 100 days after autism diagnosis guide is also worth keeping open.
Then do not just keep nudging the dose forever and hoping. Ask a better question.
If your child still cannot sleep despite good routine and a proper trial, escalate. That may mean paediatrics, a sleep clinic, CAMHS, ENT, gastro review, iron studies, or broader neurodevelopmental review. If you are stuck between "the GP says wait" and "CAMHS waitlist is miles long", document the impact clearly: school attendance, parent exhaustion, behaviour, and safety.
If the wider functional question is whether your child needs more occupational therapy support around regulation, bedtime transitions or sensory work, our guide to private vs NHS OT for children in the UK may help you think through the next move.
Common side effects include sleepiness, tiredness, headache, irritability, mood changes, aggression, and a hangover-like feeling. Most are mild. If your child is groggy in the morning, something about the timing, dose or formulation may need reviewing.
Longer-term data are also better than many parents fear. Follow-up data over up to two years with prolonged-release melatonin in autistic children did not show a clear signal of harm to growth, body mass index or pubertal development. That does not mean "monitor nothing". It means the doom-lore you sometimes hear online is not well supported by the best available data.
Things worth monitoring are simple: morning grogginess, mood, new behaviour changes, headaches, and whether sleep is still meaningfully better after the initial honeymoon period.
This is one of the few autism-related intervention pages where I can say something straightforward: for many autistic children with real insomnia, melatonin is worth considering and often helps.
But the sensible version is still the boring one: behaviour-first, right product, right timing, right pathway, and proper review if it fails. The goal is to help a child whose body clock and nervous system are making sleep unreasonably hard.
Worth noting that melatonin is the exception in autism-related research, not the rule. For everything else — bumetanide, oxytocin, leucovorin, stem cell, HBOT, neurofeedback, CBD — the same pattern of promising-then-disappointing keeps repeating. Our meta-guide on why so many autism trials fail explains why, and gives you a 5-question checklist before paying for any private intervention.
Disclaimer: SENDPath provides information for families navigating SEND in Kent and beyond. We are not clinicians. Nothing on this page constitutes medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing medication for your child.
If sleep has become impossible and everything else feels impossible too, start here for the practical early-stage map.
Read guide →If bedtime is really a sensory problem in disguise, this guide will help more than another random supplement.
Read guide →When you are stuck on a waitlist and sleep, regulation and daily life are all unravelling, this helps you think clearly about next steps.
Read guide →A useful comparison page: one intervention where the theory was exciting but the main trial was negative.
Read guide →